Sensorion to Participate in June 2024 Investor Conferences

MONTPELLIER, France--Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN), a trailblazing biotechnology company focused on developing innovative treatments for hearing loss disorders, has announced its involvement in several notable investor conferences scheduled for June 2024. The company, which operates at the clinical stage, is committed to restoring, treating, and preventing various types of hearing impairments.

June Conferences Overview

Sensorion will be represented at the Jefferies Global Healthcare Conference in New York, USA, on June 5-6, 2024. The company's management team will be available for individual meetings on June 6, providing an opportunity for direct engagement with investors.

Following this, Sensorion will participate in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, USA, from June 10-13, 2024. The team will be open for investor discussions on June 12 and 13.

Finally, Sensorion will attend Stifel’s European Healthcare Summit in Lyon, France, from June 25-27, 2024. One-on-one meetings with the company’s management will be held on June 26, offering another chance for investors to gain insights into Sensorion's advancements and future plans.

About Sensorion

Sensorion is a pioneering biotech firm focusing on creating new therapies aimed at addressing hearing loss disorders, which remain a critical unmet medical need globally. The company has developed a distinctive R&D technology platform that enhances the understanding of inner ear disease mechanisms. This platform helps in pinpointing the optimal targets and action mechanisms for potential drug candidates.

The company is currently advancing two gene therapy programs for hereditary forms of deafness. These programs are part of a strategic partnership with the Institut Pasteur, concentrating on the genetic aspects of hearing. The SENS-501 (OTOF-GT) program, now in a Phase 1/2 clinical trial, targets deafness caused by otoferlin gene mutations. Another program, GJB2-GT, addresses hearing loss linked to GJB2 gene mutations, aiming to treat significant hearing loss in both adults and children. Additionally, Sensorion is focused on identifying biomarkers to enhance the diagnosis of these under-served conditions.

Sensorion’s pipeline also includes small molecule programs in clinical stages, designed for treating and preventing hearing loss. The portfolio features one Phase 2 product, SENS-401 (Arazasetron), which is currently in a Phase 2 proof of concept study for Cisplatin-Induced Ototoxicity (CIO). This study is in collaboration with Cochlear Limited and involves patients prepared for cochlear implantation. Another Phase 2 study of SENS-401 was completed for Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!